Cure My Disease

Don't miss your cure!

 Log in / Sign up

Gene-Edited cells take on lupus and scleroderma in first human test

NCT ID NCT06925542

Recruiting now Disease control Sponsor: CRISPR Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 3 times

Summary

This early-stage trial tests a single infusion of CRISPR-edited immune cells (CTX112) from a healthy donor in 80 adults with severe lupus, scleroderma, or myositis that hasn't responded to standard treatments. The goal is to see if the cells are safe and can reduce disease activity by targeting and calming the overactive immune system. Because it's a Phase 1 study, the main focus is safety, not yet proving the treatment works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
CRISPR-edited immune cells (CTX112) from a healthy donor
What this could lead to
If it works, this could point toward a one-time treatment that resets the immune system for people with severe autoimmune diseases like lupus.
What could go wrong
This is a very early Phase 1 trial with only 80 people, so safety and effectiveness are not yet proven. There are risks from the cell infusion and possible long-term immune suppression.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANTISYNTHETASE SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acquired idiopathic inflammatory myopathy antisynthetase syndrome dermatomyositis diffuse cutaneous systemic sclerosis diffuse scleroderma idiopathic inflammatory myopathy immune-mediated necrotizing myopathy juvenile dermatomyositis lupus nephritis myositis disease polymyositis systemic lupus erythematosus systemic sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS INFLAMMATORY MYOPATHY, IDIOPATHIC LUPUS ERYTHEMATOSUS, SYSTEMIC LUPUS NEPHRITIS MYOSITIS SLE (SYSTEMIC LUPUS) SYSTEMIC SCLEROSIS

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Boston Medical Center

    RECRUITING

    Boston, Massachusetts, 02118, United States

  • Clinica Universidad de Navarra - Pamplona

    RECRUITING

    Pamplona, 31008, Spain

  • Hospital Universitario Reina Sofia

    RECRUITING

    Córdoba, 14004, Spain

  • Hospital Universitario Virgen del Rocio

    RECRUITING

    Seville, 41013, Spain

  • Manning Family Children's Hospital of New Orleans

    RECRUITING

    New Orleans, Louisiana, 70118, United States

  • Medizinische Hochschule Hannover (MHH)

    RECRUITING

    Hanover, 30625, Germany

  • Northwestern Medicine, Robert H. Lurie Comprehensive Cancer Center

    RECRUITING

    Chicago, Illinois, 63110, United States

  • Stanford University Medical Center

    RECRUITING

    Redwood City, California, 94063, United States

  • UCT University Medical Center Mainz

    RECRUITING

    Mainz, 55131, Germany

  • University of Augsburg

    RECRUITING

    Augsburg, 86156, Germany

  • University of Iowa

    RECRUITING

    Iowa City, Iowa, 52242, United States

  • University of North Carolina TraCS Institute - CTRC

    RECRUITING

    Chapel Hill, North Carolina, 27599, United States

  • Universitätsklinikum Köln

    RECRUITING

    Cologne, 50937, Germany

  • Washington University School of Medicine

    RECRUITING

    St Louis, Missouri, 63130, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.